These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 31521544)

  • 1. Dyslipidemia Management in Adults With Diabetes.
    Lazarte J; Hegele RA
    Can J Diabetes; 2020 Feb; 44(1):53-60. PubMed ID: 31521544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
    Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA
    Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent Updates on the Use of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease.
    Dixon DL; Pamulapati LG; Bucheit JD; Sisson EM; Smith SR; Kim CJ; Wohlford GF; Pozen J
    Curr Atheroscler Rep; 2019 Mar; 21(5):16. PubMed ID: 30877491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Managing dyslipidemia in patients with Type 2 diabetes.
    Tomlinson B; Patil NG; Fok M; Lam CWK
    Expert Opin Pharmacother; 2021 Nov; 22(16):2221-2234. PubMed ID: 33823719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT
    Circulation; 2019 Jun; 139(25):e1144-e1161. PubMed ID: 30586775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.
    Lloyd-Jones DM; Morris PB; Ballantyne CM; Birtcher KK; Daly DD; DePalma SM; Minissian MB; Orringer CE; Smith SC
    J Am Coll Cardiol; 2017 Oct; 70(14):1785-1822. PubMed ID: 28886926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid management beyond the guidelines.
    Robinson JG
    Prog Cardiovasc Dis; 2019; 62(5):384-389. PubMed ID: 31669499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
    Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
    JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT
    J Am Coll Cardiol; 2019 Jun; 73(24):3210-3227. PubMed ID: 30423394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm - 2020 Executive Summary.
    Handelsman Y; Jellinger PS; Guerin CK; Bloomgarden ZT; Brinton EA; Budoff MJ; Davidson MH; Einhorn D; Fazio S; Fonseca VA; Garber AJ; Grunberger G; Krauss RM; Mechanick JI; Rosenblit PD; Smith DA; Wyne KL
    Endocr Pract; 2020 Oct; 26(10):1196-1224. PubMed ID: 33471721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms and Treatment of Dyslipidemia in Diabetes.
    Bahiru E; Hsiao R; Phillipson D; Watson KE
    Curr Cardiol Rep; 2021 Mar; 23(4):26. PubMed ID: 33655372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonstatin therapies for management of dyslipidemia: a review.
    Sando KR; Knight M
    Clin Ther; 2015 Oct; 37(10):2153-79. PubMed ID: 26412799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes.
    Roe MT; Li QH; Bhatt DL; Bittner VA; Diaz R; Goodman SG; Harrington RA; Jukema JW; Lopez-Jaramillo P; Lopes RD; Louie MJ; Moriarty PM; Szarek M; Vogel R; White HD; Zeiher AM; Baccara-Dinet MT; Steg PG; Schwartz GG
    Circulation; 2019 Nov; 140(19):1578-1589. PubMed ID: 31475572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An update on pharmacotherapies in diabetic dyslipidemia.
    Gupta M; Tummala R; Ghosh RK; Blumenthal C; Philip K; Bandyopadhyay D; Ventura H; Deedwania P
    Prog Cardiovasc Dis; 2019; 62(4):334-341. PubMed ID: 31442512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2017 Taiwan lipid guidelines for high risk patients.
    Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
    J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
    Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
    JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in the Management of Dyslipidemia.
    Tziomalos K
    Curr Pharm Des; 2017; 23(10):1495-1499. PubMed ID: 28155622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 2018 Cholesterol Management Guidelines: Topics in Secondary ASCVD Prevention Clinicians Need to Know.
    Jia X; Al Rifai M; Birnbaum Y; Smith SC; Virani SS
    Curr Atheroscler Rep; 2019 Apr; 21(6):20. PubMed ID: 30941517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk.
    Orringer CE; Jacobson TA; Maki KC
    J Clin Lipidol; 2019; 13(6):860-872. PubMed ID: 31787586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.